Regeneron Pharmaceuticals Shares Sold by Amova Asset Management

Amova Asset Management reduces stake in biotech company Regeneron Pharmaceuticals

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Amova Asset Management Americas Inc. has reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.3% in the third quarter, according to a recent SEC filing. The fund now owns 20,224 shares of the biopharmaceutical company's stock, valued at $11,371,000.

Why it matters

Regeneron Pharmaceuticals is a major player in the biotech industry, known for its proprietary drug discovery technologies. Changes in institutional ownership of the company's stock can provide insights into market sentiment and potential shifts in the company's outlook.

The details

According to the filing, Amova Asset Management sold 3,090 shares of Regeneron Pharmaceuticals during the third quarter. The fund now owns 20,224 shares of the biopharmaceutical company's stock, valued at $11,371,000. Regeneron Pharmaceuticals' stock has seen strong performance, with the share price increasing from $476.49 to a 52-week high of $821.11 over the past year.

  • Amova Asset Management reduced its Regeneron Pharmaceuticals stake in the 3rd quarter of 2025.

The players

Amova Asset Management Americas Inc.

An investment management firm that has reduced its position in Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals, Inc.

A U.S.-based biotechnology company that focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions.

Got photos? Submit your photos here. ›

The takeaway

The reduction in Amova Asset Management's Regeneron Pharmaceuticals stake suggests a potential shift in market sentiment around the biotech company, though the overall outlook for Regeneron remains positive with the stock trading near all-time highs.